Lactobacillus ( DrugBank: - )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	7
46	悪性関節リウマチ	1
51	全身性強皮症	1
97	潰瘍性大腸炎	9
299	嚢胞性線維症	4

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05576818 (ClinicalTrials.gov)	June 30, 2022	10/10/2022	Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease	Clinical Study Evaluating the Efficacy and Safety of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease	Parkinson Disease	Drug: Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers	Tanta University	NULL	Recruiting	45 Years	65 Years	All	66	Phase 3	Egypt
2	NCT04871464 (ClinicalTrials.gov)	November 11, 2021	29/4/2021	Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease	Role and Mechanism of Bifidobacterium Triple Viable Capsules in Improving Motor Symptoms in Patients With Mild to Moderate Parkinson's Disease: a Multicenter Randomized Clinical Study	Parkinson Disease;Parkinsonian Disorders;Basal Ganglia Diseases;Brain Diseases;Movement Disorders;Neurodegenerative Diseases;Central Nervous System Diseases;Nervous System Diseases	Drug: Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules;Other: Placebo	Beijing Friendship Hospital	NULL	Recruiting	40 Years	85 Years	All	240	Phase 4	China
3	NCT04722198 (ClinicalTrials.gov)	October 27, 2020	15/1/2021	Effects of Lactobacillus Plantarum PS128 on Symptoms of Early-onset Parkinson's Disease: a Pilot Study	Effects of Lactobacillus Plantarum PS128 on Symptoms of Early-onset Parkinson's Disease: a Pilot Study	Early Onset Parkinson Disease	Dietary Supplement: PS128	Professor Lu Neurological Clinic	NULL	Recruiting	20 Years	80 Years	All	20	N/A	Taiwan
4	NCT04722211 (ClinicalTrials.gov)	July 6, 2020	15/1/2021	Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease.	Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease.	Parkinson Disease	Dietary Supplement: PS128;Dietary Supplement: placebo	Professor Lu Neurological Clinic	NULL	Recruiting	45 Years	80 Years	All	120	N/A	Taiwan
5	NCT04389762 (ClinicalTrials.gov)	June 4, 2019	30/4/2020	PS128 May Improve Off Duration on Parkinson's Disease	Lactobacillus Plantarum PS128 May Improve Off Duration in Parkinson's Disease: a Pilot Study	Parkinson Disease	Dietary Supplement: daily ingestion of Lactobacillus plantarum PS128	Professor Lu Neurological Clinic	NULL	Completed	40 Years	80 Years	All	60	N/A	Taiwan
6	NCT04293159 (ClinicalTrials.gov)	May 14, 2019	19/2/2020	Effect of Probiotic on Constipation in Patients With Parkinson's Disease	Effect of Probiotic on Constipation and on Neuropsychological Performance in Patients With Parkinson's Disease	Parkinson Disease;Constipation	Dietary Supplement: Lactobacillus casei DG (Enterolactis duo®)	University of Salerno	Roberto Erro;Maria Teresa Pellecchia;Antonella Santonicola;Carolina Ciacci	Recruiting	18 Years	75 Years	All	30	N/A	Italy
7	NCT03566589 (ClinicalTrials.gov)	July 2, 2018	12/6/2018	Effects of PS128 on Parkinsonian Symptoms	Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease: a Pilot Study	Parkinson Disease	Dietary Supplement: Lactobacillus plantarum PS128	Professor Lu Neurological Clinic	NULL	Completed	40 Years	80 Years	All	30	N/A	Taiwan

先頭へ

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00664820 (ClinicalTrials.gov)	March 2008	18/4/2008	Effects of Probiotics on Rheumatoid Arthritis Patients	Effects of Probiotics on Rheumatoid Arthritis Patients	Rheumatoid Arthritis	Dietary Supplement: Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14	Lawson Health Research Institute	University of Western Ontario, Canada;St. Joseph's Health Care London	Completed	18 Years	80 Years	All	50	N/A	Canada

51. 全身性強皮症

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01497743 (ClinicalTrials.gov)	February 2012	20/12/2011	Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis	Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis	Scleroderma	Drug: Lactobacillus	University of Michigan	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 4	United States

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05118919 (ClinicalTrials.gov)	February 9, 2022	26/10/2021	A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis	A Randomised Placebo-controlled Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Mild to Moderate Ulcerative Colitis	Ulcerative Colitis	Biological: BGP-014;Biological: Placebo	BioGaia Pharma AB	NULL	Recruiting	18 Years	N/A	All	50	Phase 1/Phase 2	Sweden
2	EUCTR2019-004578-25-SE (EUCTR)	09/07/2021	27/12/2019	A clinical study in patients with mild to moderate ulcerative colitis to test the tolerability of Lactobacillus reuteri BGP-014	A randomised placebo-controlled safety study of Lactobacillus reuteri BGP-014 in patients with active mild to moderate ulcerative colitis	Mild to moderate ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: BGP-014 Capsules Product Code: BGP-014 INN or Proposed INN: Lactobacillus reuteri Other descriptive name: LACTOBACILLUS REUTERI	BioGaia Pharma AB	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 1;Phase 2	Sweden
3	ChiCTR2000033953	2020-07-01	2020-06-18	Effect of the probiotic on symptoms in patients with ulcerative colitis (UC)	Effect of the probiotic on symptoms in patients with ulcerative colitis (UC)	Ulcerative colitis	Placebo group:Maltodextrin;experimental group 1:Lactobacillus plantarum CCFM8610;experimental group 2:Lactobacillus plantarum N13;experimental group 3:Lactobacillus casei CCFM1059;	Jiangnan University	NULL	Pending			Both	Placebo group:20;experimental group 1:20;experimental group 2:20;experimental group 3:20;		China
4	NCT04102852 (ClinicalTrials.gov)	September 30, 2019	17/9/2019	Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients	The Role of Lactobacillus Rhamnosus GG (ATCC 53103) in the Modulation of the Inflammatory Process in the Mucosa of Ulcerative Colitis (UC) Patients With Mild-moderate Clinical Activity	Ulcerative Colitis Chronic Mild;Ulcerative Colitis Chronic Moderate	Dietary Supplement: Lactobacillus rhamnosus GG ATCC 53103	San Giovanni Addolorata Hospital	Onlus S. Andrea	Completed	18 Years	65 Years	All	76	Phase 1/Phase 2	Italy
5	NCT03798210 (ClinicalTrials.gov)	January 1, 2017	7/1/2019	Lactobacillus Reuteri ATCC PTA 4659 in Ulcerative Colitis	The Effect of Lactobacillus Reuteri ATCC PTA 4659 in Patients With Ulcerative Colitis	Ulcerative Colitis Flare	Dietary Supplement: Lactobacillus reuteri;Dietary Supplement: Placebo	Uppsala University	NULL	Recruiting	18 Years	80 Years	All	40	Phase 2	Sweden
6	NCT03136419 (ClinicalTrials.gov)	October 31, 2016	5/4/2017	Microbiota and Immune microEnvironment in Pouchitis	Microbiota and Immune microEnvironment in Pouchitis: Randomized Controlled Trial Oral Administration of Lactobacillus Casei DG After Ileostomy Closure in Ileal Pouch Mucosa	Pouchitis;Ulcerative Colitis;Ileal Pouch	Dietary Supplement: Lactobacillus casei DG;Dietary Supplement: Placebo	University of Padova	NULL	Recruiting	18 Years	100 Years	All	32	N/A	Italy
7	NCT00895336 (ClinicalTrials.gov)	March 2011	27/4/2009	Lactobacillus GG in Pediatric Ulcerative Colitis (UC)	An Open Label Pilot Study of Lactobacillus GG in Pediatric Ulcerative Colitis	Ulcerative Colitis	Biological: Lactobacillus GG	Children's Hospital Medical Center, Cincinnati	NULL	Withdrawn	5 Years	18 Years	All	0	Phase 2	United States
8	NCT00268164 (ClinicalTrials.gov)	June 2004	21/12/2005	Lactobacillus Acidophilus and Bifidobacterium Animalis Subsp. Lactis, Maintenance Treatment in Ulcerative Colitis	Lactobacillus Acidophilus and Bifidobacterium Animalis Subsp. Lactis, Maintenance Treatment in Ulcerative Colitis	Ulcerative Colitis	Drug: lactobacilus acidophilus & bifidobacterium animalis/lactis	Hvidovre University Hospital	Chr Hansen A/S	Terminated	18 Years	N/A	Both	48	Phase 2	Denmark
9	NCT00510978 (ClinicalTrials.gov)	January 2002	2/8/2007	Probiotics in GastroIntestinal Disorders	One Year, Randomised, Double Blind, Placebo Controlled Trial of Probiotics, Bifidobacterium Infantis 35624 or Lactobacillus Salivarius UCC118, as Food Supplements for Maintenance of Remission in Crohn's Disease and Ulcerative Colitis	Ulcerative Colitis;Crohn's Disease	Biological: Bifidobacterium infantis 35624;Biological: Lactobacillus salivarius UCC118;Biological: Placebo	University College Cork	European Commission	Active, not recruiting	N/A	75 Years	Both	360	Phase 2/Phase 3	Ireland

先頭へ

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01837355 (ClinicalTrials.gov)	March 2013	10/4/2013	Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Diet Supplementation in Pediatric Cystic Fibrosis	Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Rhamnosus Diet Supplementation in Pediatric Cystic Fibrosis (MoHuM-1)	Pulmonary Inflammation;Cystic Fibrosis;Microbiota	Dietary Supplement: Lactobacillus rhamnosus;Dietary Supplement: Placebo	Cantonal Hospital of St. Gallen	Swiss Federal Institute of Technology;University Hospital Inselspital, Berne	Unknown status	6 Years	20 Years	All	68	N/A	Switzerland
2	NCT01956916 (ClinicalTrials.gov)	October 2010	23/9/2013	Probiotics in Cystic Fibrosis	Effects of LGG Administration in Children With Cystic Fibrosis: A Randomized Controlled Trial	Cystic Fibrosis	Dietary Supplement: Lactobacillus rhamnosus GG;Dietary Supplement: placebo	Federico II University	NULL	Completed	2 Years	18 Years	Both	110	Phase 3	Italy
3	NCT01961661 (ClinicalTrials.gov)	September 2009	9/10/2013	Probiotics on Intestinal Inflammation in Cystic Fibrosis	Effect of Probiotics on Intestinal Inflammation and Microflora in Cystic Fibrosis: a Pilot Study	Cystic Fibrosis	Dietary Supplement: Lactobacillus rhamnosus GG;Dietary Supplement: placebo	Federico II University	NULL	Completed	2 Years	18 Years	Both	22	Phase 3	Italy
4	NCT01737983 (ClinicalTrials.gov)	May 2009	12/7/2012	Effect of Lactobacillus Reuteri in Cystic Fibrosis	Lactobacillus Reuteri Reduces Pulmonary Exacerbations and Upper Respiratory Tract Infections in CF Patients With Mild-to-moderate Lung Disease. LR Administration Might Have a Beneficial Effect on the Disease Course of Cystic Fibrosis.	CYSTIC FIBROSIS	Dietary Supplement: Lactobacillus reuteri;Dietary Supplement: placebo	Azienda Policlinico Umberto I	NULL	Completed	6 Years	42 Years	Both	61	Phase 4	Italy

先頭へ